Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 6/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068649 | 1.00 | SMPD3 (0.46) | SMPD3METAP2CCNT1CDK4CCND1 | |
| SCHEMBL2069373 | 1.00 | SMPD3 (0.46) | SMPD3METAP2CCNT1CDK4CCND1 | |
| SCHEMBL2411684 | 0.84 | SMPD3 (0.48) | SMPD3METAP2PDE10APRKDCCDK1 | |
| SCHEMBL14938741 | 0.83 | MAP4K4 (0.40) | SMPD3PDE10A | |
| SCHEMBL2413653 | 0.83 | SMPD3 (0.47) | SMPD3METAP2PDE10APRKDCCDK1 | |
| Hydrochloric Acid SCHEMBL6336102 | 0.83 | SMPD3 (0.47) | SMPD3METAP2PDE10APRKDCCDK1 | |
| SCHEMBL15515890 | 0.82 | METAP2 (0.46) | SMPD3METAP2CCNT1CDK4CCND1 | |
| SCHEMBL15509173 | 0.82 | METAP2 (0.46) | SMPD3METAP2CCNT1CDK4CCND1 | |
| SCHEMBL15509072 | 0.82 | METAP2 (0.46) | SMPD3METAP2CCNT1CDK4CCND1 | |
| SCHEMBL2411465 | 0.81 | PRKAB2 (0.48) | SMPD3PDE10APRKDCIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | SMPD3 1264/4885METAP2 4283/4885CCNT1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.